However, little is known about the SR protein binding sites within t h e s e enhancer sequences, although it appears that SR p r o t e i n -d e p e n d e n t splicing specificity is mainly due to the RRM domains (40, 41) .
Splicing of the last intron (intron D) of the bovine growth h o r m o n e (bGH) pre-mRNA requires the presence of a downstream splicing e n h a n c e r in the last exon (17, 42) . This ESE is contained within a 115-nucleotide Fsp I-P v u II (FP) fragment in the middle of exon 5 (42) . The SR protein SF2/ASF binds specifically to the FP region and, presumably as a result of this binding, it enhances splicing of bGH intron D in vitro (19) . Although there is evidence that a purine-rich sequence in the middle of the FP sequence is part of the bGH ESE sequence (17), it was not clear w h e t h e r SF2/ASF binds to this purine-rich sequence and/or to adjacent regions. I n this study, we take advantage of the fact that SF2/ASF binds to the FP sequence in the absence of other proteins, and utilize this simplified recognition event to study one of the earliest steps in splicing, ESE recognition. Mapping of SF2/ASF cross-links to the FP sequence and EMSA showed that there are multiple SF2/ASF binding sites within the FP sequence, including a site that is centered around the previously described purine motif (17) . The functional significance of these SF2/ASF binding 
Experimental Procedures
Materials. The plasmids pbGH-4D5 (43) , pE5/FP (19) and pSP64-Hβ∆6 (44) have been described. pSP64-Hβ∆6 was subcloned into the pBS M13+ vector (Stratagene) to drive expression of β-globin from the T3 promoter.
Plasmid p∆UV-XL was constructed by creating a polymerase chain reaction (PCR)-derived fragment of bGH using oligonucleotide BS-44 (5'-GCCTGTAGG GGAGGGTGGAA-3') and oligonucleotide ∆UV-XL (5'-ACGTCTCCGTGCAGACCG TAG-3') as upstream and downstream primers, respectively. This f r a g m e n t was then subcloned into the Apa I and Rsa I sites of pbGH/4D5. Plasmid pUV-XL was constructed by creating a PCR-derived fragment of bGH using oligonucleotide T3 (5'-ATTAACCCTCACTAAAG-3') and oligonucleotide UV-1 0 downstream primer varied according to the FP subfragment inserted: FP subfragment no. 1 (5'-CGCGTCGTCACTGCGCATGTTTGTG-3'); FP subfragment no. 2 (5'-TAGTTCTTGAGCAGGCATGTTTGTG-3'); FP subfragment no. 3 (5'-CA GGAGAGCAGACCGGCATGTTTGTG-3'); FP subfragment no. 4 (5'-CAGGTCCTTC CGGAAGGCATGTTTGTG-3'); FP subfragment no. 5 (5'-TACGTCTCCGTCTTATG GCATGTTTGTG-3'); FP subfragment no. 6 (5'-CATGACCCTCAGGTGCATGTTTG TG-3'); FP subfragment no. 7 (5'-AGCGGCGGCACTTCGCATGTTTGTG-3'); FP subfragment no. 8 (5'-CTGGCCTCCCCGAAGCATGTTTGTG-3'); FP subfragment no. 9 (5'-CCCTCAGGTACGTCTCCGCATGTTTGTG-3').
Oligonucleotides T3 primer (5'-ATTAACCCTCACTAAAG-3') and FP17mer (5'-CTGGCCTCCCCGAAGCG-3') were purchased from National 1 1
Expression system (Clontech) and purified using a Ni-agarose affinity resin (Life Technologies) according to instructions of the manufacturer. Human recombinant hnRNP A1 (0.2 mg/ml) was expressed in E. coli and purified as described (47). Protein concentrations were determined by the d y ebinding assay (Bio-Rad) with bovine serum albumin (BSA) as a standard.
The anti-SF2/ASF monoclonal antibody (mAb96) is specific and does n o t cross-react with other SR proteins (48). The anti-hnRNP A1 mAb 4B10 w a s a generous gift from Drs. G. Dreyfuss and S. Piñol-Roma.
Mapping of specific SF2/ASF and hnRNP A1 ultraviolet ( U V ) -cross-links to the FP sequence by reverse t r a n s c r i p t i o n . [α-32 P]
GTP-labeled E5/FP RNA (16-18 ng/0.4 pmol) was incubated u n d e r standard splicing conditions (43) with either 266 ng of SF2/ASF purified t o apparent homogeneity from HeLa cells or 400 ng of purified recombinant hnRNP A1 in 25-µ l reactions at 30°C for 25 min. The reaction mixtures were then transferred to a microtiter plate and exposed to UV light ( 2 5 4 nm) at a distance of 4 cm for 15 min on ice using a UV lamp (15 Watts; G15T8, General Electric). Anti-SF2/ASF monoclonal antibody mAb96 ( 1 0 0 15 min at 4°C. The monoclonal antibody/protein A-agarose complexes were resuspended in 500 µl of IP buffer and the bound, cross-linked SF2/ASF-E5/FP RNA and hnRNP A1-E5/FP RNA reactions were added. T h e suspensions were mixed at 4°C for 2 hrs. After three washes with 1 ml of IP buffer for 15 min at 4°C, the cross-linked E5/FP RNAs were recovered by incubating the beads in 400 µl of 25 mM Tris-HCl (pH 7.4), 50 mM NaCl, 5 mM EDTA, 0.5% SDS, and 0.5 µ g/µ l Proteinase K for 30 min at 37°C w i t h intermittent mixing, followed by phenol/chloroform extraction and ethanol precipitation.
The purified RNAs were then reverse transcribed with Superscript I I Cross-links judged to be specific for SF2/ASF or hnRNP A1 were compiled and are shown in Figure 2 . The relative size of the vertical bar over o r under a specific nucleotide in Figure 2 reflects the degree to which a particular cross-link can be distinguished from background bands in t h e control lanes. The SF2/ASF cross-links are centered around the purine-rich sequence described previously (underlined in Figure 2 To test specifically for t h e requirement for SF2/ASF in splicing, the reactions were performed i n dilute nuclear extract supplemented with optimal amounts of recombinant baculovirus-produced SF2/ASF (23,50). Under dilute nuclear extract conditions, the four substrates spliced very poorly (lanes 5, 7, 9, and 11).
Addition of 0.125 µg of recombinant SF2/ASF led to increased splicing of both the wild-type substrate (lane 6) and the ∆UV-XL substrate (lane 10).
However, the level of splicing of the ∆UV-XL substrate was consistently lower than that of the wild-type substrate in parallel reactions supplemented with a range of SF2/ASF concentrations (data not shown).
As expected, the ∆FP substrate did not splice after supplementation w i t h recombinant SF2/ASF (lane 12). Interestingly, the UV-XL substrate spliced upon supplementation of the dilute nuclear extract with recombinant SF2/ASF (lane 8), but at lower levels than the wild-type and ∆UV-XL substrates. This difference was consistent over a range of SF2/ASF concentrations (data not shown).
The question remains as to why UV-XL spliced so poorly i n comparison to wild-type and ∆UV-XL substrates, given that cross-links t o SF2/ASF were only observed within the 29-nucleotide (UV-XL) sequence.
Perhaps the 29-nucleotide sequence is indeed a strong SF2/ASF binding To more precisely map the additional SF2/ASF binding sites p r e s e n t in the FP sequence, this region was divided into 14-17 nucleotide subfragments, which were inserted into the FP-deleted exon 5 (E5/∆FP) i n place of the FP sequence. These RNAs were used in the EMSA described pre-mRNA substrates at a concentration of 0.5 µM each ( Figure 6 ). A t concentrations higher than 0.5 µM, we began to observe non-specific effects for some of the oligoribonucleotides, i.e. inhibitory effects that a r e not dependent on annealing of the oligoribonucleotide to the RNA substrate (data not shown). Because of the need to keep the oligoribonucleotide concentrations as low as possible in order to avoid non-specific effects, w e found that, in contrast to some studies (51,52), inhibition was improved b y pre-incubating the oligoribonucleotides with the splicing substrate for 1 5 -30 minutes at 0°C prior to addition of the nuclear extract.
As can be seen in Figure 6 , oligoribonucleotides B7 and B8 do n o t significantly inhibit bGH pre-mRNA splicing (lanes B7 and B8) which is consistent with the fact that E5/∆FP RNA does not contain strong SF2/ASF binding sites (19). Oligoribonucleotide B6 also does not significantly affect splicing, consistent with the EMSA data in Figure 5 showing little or n o SF2/ASF binding to subfragment no. 8, which is complementary t o oligoribonucleotide B6. In addition, oligoribonucleotide B5, which spans a weak and a moderate SF2/ASF binding sites (FP subfragments 6 and 7), has only a minor effect on intron D splicing (lane 6). On the other hand, oligoribonucleotides B3 and B4 significantly inhibit bGH pre-mRNA splicing (lanes 4 and 5). These two oligoribonucleotides are complementary to t h e 29-nucleotide UV-XL sequence, and thus, it would be expected that t h e y inhibit bGH pre-mRNA splicing by blocking specific SF2/ASF binding sites. Additionally, there is a preference for pyrimidines over purines in crosslinking (58). Thus, it is possible that SF2/ASF does in fact bind to t h e purine motif identified earlier (17,30), but that this interaction does n o t lead to formation of a cross-link.
Deletion of a 29-nucleotide sequence (UV-XL) containing this putative SF2/ASF binding site(s) led to only a 50% reduction in t h e SF2/ASF-mediated stimulation of intron D splicing as compared to wildtype bGH pre-mRNA ( Figure 3 ). In addition, this sequence by itself functioned only as a moderate splicing enhancer, even though it clearly bound SF2/ASF (Figure 4) . Although it is possible that these effects w e r e caused by the deletion mutants affecting the secondary structure of bGH pre-mRNA, we do not believe this to be the case. Extensive analyses of bGH mRNA secondary structure, using Zuker's computer algorithm (60-62) i n combination with previous experimental data obtained with s t r u c t u r esensitive probes (for example, RNAses T1 and V1) has not suggested a n y obvious alterations. Instead, we favor the hypothesis that additional to be functional, since the ∆UV-XL pre-mRNA never splices better than t h e wild-type bGH pre-mRNA ( Figure 3) . Thus, the precise location of SF2/ASF binding sites within the enhancer and the interrelationship between t h e various SF2/ASF binding sites appear to be important factors i n determining enhancer function.
In an attempt to locate the additional SF2/ASF binding sites, the FP sequence was divided into similar sized subfragments of 1 4 -1 7
nucleotides. These subfragments were inserted into bGH exon 5 in place of the entire FP sequence. EMSA analysis of these FP subfragments s h o w e d that they could be divided into three groups: those that showed little or n o binding to SF2/ASF (subfragment nos. 6 and 8), those that s h o w e d moderate binding to SF2/ASF (subfragment nos. 1, 3 and 7), and those t h a t showed strong binding to SF2/ASF (subfragment nos. 2, 4, 5 and 9). T h e SF2/ASF cross-links that were mapped in Figure 1A 
